Alopexx's IPO
3,000,000 shares at $10 to $12 (amended S-1 of Sep 17, 2026). No day set yet.
Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.
Once Alopexx lists, Breakaway scores it against every US stock
- Its Quality Score from its second session, ranked against 3,191 stocks
- Every insider trade, the day it is filed
- The lock-up's end on your calendar, once the prospectus dates it
- An alert when its score is first set, and when it turns
See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.
What does Alopexx do?
“We are a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG).”
| Fact | Alopexx |
|---|---|
| Founded | 2006 |
What is the offering?
Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.
| Fact | Alopexx |
|---|---|
| Shares offered | 3,000,000 |
| Price range | $10 to $12 a share |
| Underwriters' option | 450,000 more shares |
| Underwriter | ThinkEquity |
| Exchange | NYSE American (applied to list) |
| Shares outstanding after | 8,350,506 |
| Market cap at the midpoint | $91.9 million |
What risks does Alopexx name first?
- “We are in the early stages of clinical development and have a very limited operating history and no products approved for commercial sale, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.”
- “We anticipate that we will continue to incur substantial net losses for the foreseeable future and may never achieve or maintain profitability.”
- “Our history of recurring losses and anticipated expenditures raises substantial doubts about our ability to continue as a going concern.”
Every date of Alopexx's IPO
| What | Day |
|---|---|
| Registration filed | Sep 9, 2024 |
| Price range set | Sep 17, 2026 |
| Lock-up | 180 days |
The other IPOs expected
| Company | Price |
|---|---|
| $19 to $21 | |
| $15 to $17 | |
| $15 to $17 | |
| $7 | |
| $5 to $7 |
Alopexx IPO questions
When is Alopexx's IPO?
3,000,000 shares at $10 to $12 (amended S-1 of Sep 17, 2026). No day set yet.
What is Alopexx's IPO price?
Alopexx set a range of $10 to $12 a share in its amended S-1 of Sep 17, 2026. The final price is set the evening before it lists.
How many shares is Alopexx selling?
3,000,000 shares, and the underwriters may buy 450,000 more, per its amended S-1.
Who are the underwriters?
ThinkEquity, as the prospectus's cover names them.
When does the lock-up end?
Its prospectus sets a lock-up of 180 days; the day it ends is read from its final prospectus once it lists.
Does Breakaway rate Alopexx?
Breakaway scores a new stock from its second trading day, ranked against every US stock it scores. For its first 21 sessions the page says New listing in place of the tier, and each check that needs more history waits for it.
Can Breakaway say where Alopexx's price will go?
No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Once Alopexx lists, Breakaway scores it against every US stock
- Its Quality Score from its second session, ranked against 3,191 stocks
- Every insider trade, the day it is filed
- The lock-up's end on your calendar, once the prospectus dates it
- An alert when its score is first set, and when it turns
See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.